Clinical Trials Logo

Female Stress Incontinence clinical trials

View clinical trials related to Female Stress Incontinence.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06451796 Recruiting - Clinical trials for Female Stress Incontinence

Investigation of Novel Non-CE Marked Catheter

Start date: June 18, 2024
Phase:
Study type: Observational

Hypothesis: Treatment with the hydrophilic coated valved intraurethral catheter up to 16 hours per day is effective, well tolerated and seemingly safe for treatment of women with stress incontinence. Test persons: Ten to twenty stress incontinent women. Treatment time: Up to two weeks

NCT ID: NCT05448482 Recruiting - Clinical trials for Female Stress Incontinence

Hybrid Versus Synthetic TOT for Treatment of SUI

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

This prospective study is conducted on female patients presenting with SUI at Alexandria main university hospital. Patients with neurogenic voiding dysfunction, history of anti-incontinence surgery, urge-predominant MUI, urogenital cancer, pelvic irradiation, body mass index more than 40 kg/m2 and more than stage 1 POP are excluded. Patients are randomized into 2 groups, one group will be subjected to h_TOT, and the second group to conventional TOT. Patients are subjected to PGI and UDI-6 questionnaires and a urodynamic study before and 6 months after the both surgery. Success is defined as: no subjective complaint of SUI, negative cough stress test and no leakage on UDS.

NCT ID: NCT03996070 Recruiting - Clinical trials for Female Stress Incontinence

VESPER: Stress Urinary Incontinence STUDY

VESPER-SUI
Start date: June 6, 2022
Phase: N/A
Study type: Interventional

Patients seen with stress urinary incontinence (SUI) that have failed conservative treatments will be offered to participate in a sham controlled RCT of outpatient therapy with the Fotona Smooth Erbium Yag laser. Patients will be randomised to either outpatient laser treatments or sham treatments. Patients will be blinded to which arm they have been randomised. Patients will be asked to complete appropriate relevant symptom and quality of life questionnaires prior to treatment and then at 6 and 12 months following the final treatment. At 6 months Sham patients will be un-blinded and offered the laser therapy if they wish.